文献速递皮肤肿瘤药疹与重症皮肤不良反应

免疫检查点抑制剂诱导的黑素瘤患者胰腺酶升高:发生率、管理与治疗的多中心分析

Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy-A multicentre analysis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2024-11-20

这项多中心回顾性分析纳入1516例接受ICI治疗的黑素瘤患者,204例出现≥CTCAE II°脂肪酶升高,其中41例(20.1%)有胰腺炎症状。近半数患者因胰腺不良事件中断或停用免疫治疗,103例(50.5%)接受全身糖皮质激素。作者提出管理算法,建议脂肪酶检测限于有症状或影像学提示胰腺损伤的患者。

要点

  • ICI治疗黑素瘤患者中≥CTCAE II°脂肪酶升高发生率高于既往报道。
  • 无症状患者影像学证实胰腺炎罕见,但免疫治疗常被暂停或终止。
  • 建议脂肪酶检测限于有症状和/或影像学提示胰腺损伤的患者。

核心结论

  • 接受ICI治疗的黑素瘤患者中血清脂肪酶升高比近期报道更常见,但无症状患者影像学胰腺炎罕见。
  • 尽管临床相关性不确定,免疫治疗常因胰腺不良事件暂停或终止,且半数患者接受全身糖皮质激素。
  • 作者提供算法以指导潜在胰腺不良事件的监测与管理。

研究设计与样本

  • 奥地利和瑞士八家皮肤肿瘤中心合作开展的回顾性队列分析。
  • 纳入1516例接受ICI治疗的黑素瘤患者,分析ICIPI发生率和管理。
  • 另进行基于问卷的ICIPI管理调查。

主要发现

  • 1516例患者中204例出现≥CTCAE II°脂肪酶升高。
  • 204例中41例(20.1%)有提示胰腺炎的症状。
  • 近半数患者因胰腺不良事件中断或停用免疫治疗。
  • 103例(50.5%)接受全身糖皮质激素,有症状者剂量更高。
  • 无症状患者中6%有影像学证实的胰腺炎,这些患者最大脂肪酶升高均>5xULN。

关键数值与推荐

  • 所有参与中心均进行常规脂肪酶监测,尽管相关指南未推荐。
  • 脂肪酶检测应限于有症状的患者和/或影像学提示胰腺损伤的患者。

临床怎么用

  • 对ICI治疗患者,尤其出现胰腺相关症状时,应监测脂肪酶。
  • 无症状患者不推荐常规脂肪酶监测,以避免不必要的免疫治疗中断。
  • 影像学提示胰腺损伤或症状明显者,可考虑糖皮质激素治疗。

局限性

  • 回顾性研究设计。
  • 未明确报告影像学胰腺炎的具体诊断标准。
  • 管理算法基于专家意见,需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICI) are considered standard-of-care in the systemic treatment of melanoma. However, management of certain ICI-associated adverse events (AE) can be challenging. Incidence, course and management of immune checkpoint inhibitor-induced pancreatic injury (ICIPI) are not well-documented and specific diagnostic and therapeutic algorithms are lacking. Current management includes serological monitoring of pancreatic enzymes, radiographic imaging and corticosteroid or further immunosuppressive treatment. OBJECTIVES: Based on previous data regarding adjuvant ICI treatment, we suspected that elevation of pancreatic enzymes may occur more frequently than reported while the clinical relevance of-particularly asymptomatic-ICIPI is still unclear. METHODS: A collaboration of eight Austrian and Swiss dermato-oncology centres was established to retrospectively analyse a large cohort of ICI-treated patients regarding incidence and management of ICIPI. Additionally, a questionnaire-based survey concerning ICIPI-management was conducted. RESULTS: Among 1516 melanoma patients receiving ICI therapy, 204 patients exhibited ≥CTCAE II° lipase elevation. Of these patients, 41 (20.1%) had symptoms suggestive of pancreatitis. Immunotherapy was interrupted or discontinued due to pancreatic AE in almost half of the patients. Systemic corticosteroids were administered in 103 patients (50.5%), with higher doses reported in symptomatic cases. Six per cent of asymptomatic patients had radiographically proven pancreatitis. Maximum lipase elevation was >5xULN in all of these patients. CONCLUSIONS: Routine lipase monitoring was conducted in all participating centres, although not recommended in respective guidelines. Elevation of serum lipase was observed more frequently than recently reported. Although radiographic findings indicating pancreatitis were rare in asymptomatic patients, ICI treatment was frequently paused or discontinued and systemic steroids were administered. To reduce the existing uncertainty in routine clinical practice reflected by our findings, we provide an algorithm to guide the monitoring and management of potential pancreatic adverse events. Lipase measurement should be limited to symptomatic patients and/or those with radiographic findings indicative of pancreatic injury.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Brandlmaier M, Hoellwerth M, Silly T, et al. Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy-A multicentre analysis. J Eur Acad Dermatol Venereol. 2024. PMID: 39564987. doi:10.1111/jdv.20384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。